Since July 2024, faricimab has also been approved in Europe ... However, according to the study design, individual adjustment of the dosing regimen was only possible in the second, non-comparative ...

Limitations include a small sample size, retrospective design, and potential selection bias. Although intravitreal faricimab helped to decrease central subfield thickness (CST) in patients with ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...

However, according to the study design, individual adjustment of the ... in which all patients also received treatment with faricimab. Accordingly, a relevant proportion of patients continued ...

Roche said the TENAYA and LUCERNE studies achieved their goal, with faricimab producing comparable improvements in vision when dosed every 16 weeks, compared with Bayer/Regeneron’s Eylea ...

However, recent real-world data for faricimab has confirmed its efficacy and safety. “We’ll await longer-term data to look at really that annualized injection burden and long-term treatment ...

Roche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody showed comparable results in diabetic macular oedema (DME) but with half the ...